Published in Cancer Lett on December 23, 2016
YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. Biomedicine (Taipei) (2017) 0.77
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res (2002) 28.38
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell (1993) 20.72
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20
Recent advances in head and neck cancer. N Engl J Med (2008) 5.05
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res (2000) 2.00
Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci (1999) 1.85
Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol (2008) 1.52
Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract (2006) 1.47
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res (2010) 1.24
Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal (2005) 1.22
Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene (2009) 1.18
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) (2011) 1.13
Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J (2011) 1.12
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther (2013) 1.10
Promising new molecular targeted therapies in head and neck cancer. Drugs (2013) 1.07
YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther (2012) 1.07
PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene (2010) 1.06
An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett (2005) 1.05
Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol (2004) 0.97
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. Oncology (2014) 0.97
Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface? J Clin Oncol (2013) 0.96
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol (2013) 0.95
Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer (2008) 0.95
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol (2013) 0.93
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.93
Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res (2010) 0.93
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther (2014) 0.92
Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther (2007) 0.91
Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide (2009) 0.90
The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. Cancers (Basel) (2014) 0.89
Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev (2013) 0.89
Membrane guanylate cyclase, a multimodal transduction machine: history, present, and future directions. Front Mol Neurosci (2014) 0.87
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. Eur J Pharmacol (2012) 0.86
Induction of apoptosis by type Iβ protein kinase G in the human breast cancer cell lines MCF-7 and MDA-MB-468. Cell Biochem Funct (2011) 0.86
Type II cGMP-dependent protein kinase inhibits ligand‑induced activation of EGFR in gastric cancer cells. Mol Med Rep (2014) 0.86
Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. DNA Cell Biol (2015) 0.85
cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem (2010) 0.85
The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett (2008) 0.82
Reversal of radiation-induced cisplatin resistance in murine fibrosarcoma cells by selective modulation of the cyclic GMP-dependent transduction pathway. Br J Cancer (1995) 0.81
Structures of soluble guanylate cyclase: implications for regulatory mechanisms and drug development. Biochem Soc Trans (2014) 0.79
Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells. PLoS One (2015) 0.78
Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol (2013) 0.78
β‑catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl‑xl. Mol Med Rep (2016) 0.77
Current concepts of organ preservation in head and neck cancer. Eur Arch Otorhinolaryngol (2010) 0.77
Riociguat for pulmonary hypertension. Expert Rev Clin Pharmacol (2014) 0.77
The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Lett (2015) 0.76